Vice President of Market Research at Industry Standard Research Rebecca McAvoy analyzes results from a recent study indicating that COVID-19 has made sponsors more willing to run hybrid trials.
“In a November 2020 survey, Industry Standard Research (ISR) asked 121 clinical trials outsourcers at sponsor companies a series of questions about their company’s use of hybrid trials. Hybrid trials were defined as the category of trials in which patients participate from home for some visits/activities rather than in a clinical setting. Forty-one percent of respondents indicated that their companies were currently using hybrid trials and another 32% say their companies have plans to start using hybrid trials in the next two years.”
Read the full article at Clinical Leader, and check out our Clinical Development Outsourcing Models report to see where these data come from. Keep an eye out for our upcoming Hybrid Trials-focused report, coming Q3 2021.
